Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma Inc.

An announcement from Cue Energy Resources Limited ( ($AU:CUE) ) is now available. Cue Energy Resources Limited, an ASX-listed energy company, opera...

Cue Energy seeks ASX quotation for 924,074 new ordinary shares

An update from Cue Energy Resources Limited ( ($AU:CUE) ) is now available. Cue Energy Resources Limited has issued 924,074 fully paid ordinary sha...

Cue Energy Issues New Shares Via Cashless Option Exercise

The latest announcement is out from Cue Energy Resources Limited ( ($AU:CUE) ). Horizon Oil Limited has declared its off-market takeover bid for al...

Horizon Oil Declares Cue Energy Takeover Unconditional and Speeds Up Payout

An announcement from Cuentas ( ($CUEN) ) is now available. On June 8, 2026, Cuentas’ board appointed finance executive Eric Kilinsky as interim chi...

Cuentas Names Interim CFO, Elevates AI Leadership Role

Cue Energy Resources Limited ( ($AU:CUE) ) just unveiled an announcement. Cue Energy’s independent board committee has reaffirmed its unanimous rec...

Cue board urges shareholders to reject Horizon’s best-and-final takeover bid

Cue Biopharma ( ($CUE) ) has shared an update. On May 29, 2026, Cue Biopharma announced that directors Jill Broadfoot, Peter Kiener, Frank Morich a...

Cue Biopharma Streamlines Governance and Strengthens Leadership Team

The latest update is out from Cue Energy Resources Limited ( ($AU:CUE) ). Horizon Oil Limited has launched an off-market takeover bid for all Cue E...

Market Cap	$54.56M	P/E Ratio	NaN
52W High	$41.42	52W Low	$4.97
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	81.6%	52W Position	64.4%
Overall Score	69	Value Score	60
Quality Score	65	Technical Score	83

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CUE	$28.46	+6.47%	197.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CUE	$28.46	+6.5%	197.84K
3
4
5
6

CUE

CUE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Cue Biopharma Inc. Data in Excel

Get Cue Biopharma Inc. Data in Excel